United Therapeutics Co. (UTHR) Expected to Post Quarterly Sales of $415.80 Million
Equities research analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will post $415.80 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for United Therapeutics’ earnings. The highest sales estimate is $477.41 million and the lowest is $391.90 million. United Therapeutics posted sales of $409.00 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.7%. The company is scheduled to issue its next quarterly earnings results on Wednesday, February 28th.
On average, analysts expect that United Therapeutics will report full-year sales of $415.80 million for the current year, with estimates ranging from $1.65 billion to $1.74 billion. For the next year, analysts expect that the company will post sales of $1.38 billion per share, with estimates ranging from $1.29 billion to $1.47 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The company had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same period in the prior year, the firm posted $4.23 EPS. The business’s revenue was up 9.1% compared to the same quarter last year.
Shares of United Therapeutics (NASDAQ:UTHR) traded down $0.39 during mid-day trading on Wednesday, reaching $135.22. The company’s stock had a trading volume of 375,400 shares, compared to its average volume of 552,592. United Therapeutics has a 12 month low of $112.01 and a 12 month high of $169.89. The firm has a market cap of $5,859.85, a price-to-earnings ratio of 11.96 and a beta of 1.42.
In related news, CEO Martine A. Rothblatt sold 1,258 shares of the stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $122.08, for a total transaction of $153,576.64. Following the completion of the sale, the chief executive officer now owns 2,327 shares in the company, valued at approximately $284,080.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,265 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $119.70, for a total value of $151,420.50. Following the sale, the chief executive officer now owns 2,334 shares of the company’s stock, valued at approximately $279,379.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,669 shares of company stock valued at $2,755,543. 7.80% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. HPM Partners LLC lifted its position in shares of United Therapeutics by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after buying an additional 15 shares during the period. First Allied Advisory Services Inc. lifted its position in shares of United Therapeutics by 0.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after buying an additional 19 shares during the period. Synovus Financial Corp lifted its position in shares of United Therapeutics by 1.2% during the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after buying an additional 69 shares during the period. Ifrah Financial Services Inc. lifted its position in shares of United Therapeutics by 1.7% during the 2nd quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock worth $576,000 after buying an additional 76 shares during the period. Finally, Alps Advisors Inc. lifted its position in shares of United Therapeutics by 2.3% during the 2nd quarter. Alps Advisors Inc. now owns 3,827 shares of the biotechnology company’s stock worth $496,000 after buying an additional 86 shares during the period.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.